C. Costa

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

ABSTRACT Background Topical ruxolitinib, a selective JAK1/2 inhibitor, is the first approved topical therapy for repigmentation in non‐segmental vitiligo in patients aged 12 years and older. Real‐world data in adolescents remains limited. Objectives To evaluate the real‐world eff...